Fosamax (alendronate) to PREVENT osteoporosis in postmenopausal women

November 1997

Merck is now promoting Fosamax (alendronate) to PREVENT osteoporosis in postmenopausal women.

It was initially approved just for treatment.

Fosamax slows bone loss and increases bone density. It seems to work as well as estrogen to prevent osteoporosis.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

New technology is helping pharmacists provide pharmaceutical care
Parkinson Disease Two new drugs for Parkinson's just hit the market
Parkinson Disease Tasmar is the first in a new class
Osteoporosis Fosamax (alendronate) to PREVENT osteoporosis in postmenopausal women
Hepatitis C lamivudine (3TC) for chronic hepatitis B
Hepatitis C more attention these days on hepatitis C
Cholesterol Cardiem, a new supplement to lower cholesterol
Neurology & Pain Copaxone (glatiramer acetate) for multiple sclerosis
Neurology & Pain new antiepileptic, Gabitril (tiagabine)
Women's Health treating severe premenstrual symptoms with SSRIs
which vit E supplements are best
asking about alpha lipoic acid (thioctic acid)
Hypertension new angiotensin II antagonists
Famvir and Valtrex for long-term therapy
Combivir, the first combo tablet for HIV
The FDA will approve thalidomide
metered-dose inhalers (MDIs) instead of a nebulizer to treat ACUTE asthma or COPD
Practice You'll soon see ads for Zantac 75